Shandong Xinhua Pharmaceutical Co (HKSE:00719) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00719 Shandong Xinhua Pharmaceutical Co Ltd HKSE:00719
93 GF Score
Price HK$6.19
GF Value HK$7.50
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shandong Xinhua Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Shandong Xinhua Pharmaceutical Co Valuation Rank Related Terms

HKSE:00719
93GF Score
Shandong Xinhua Pharmaceutical Co Ltd HKSE:00719
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shandong Xinhua Pharmaceutical Co (HKSE:00719) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued. The current stock price of HK$6.19 is trading 17.5% below its estimated GF Value™ of HK$7.50. GuruFocus considers Shandong Xinhua Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for HKSE:00719:

  • Valuation Rank:
  • GF Value™: HK$7.50 vs. price of HK$6.19 (17.5% below fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the HKSE:00719 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Xinhua Pharmaceutical Co Business Description

Other Exchanges XIN:Germany000756:China
Address No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
93GF Score

Get the complete analysis for HKSE:00719

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.19
Price
HK$7.50
GF Value